Ablative Prostate Boost + Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Intermediate Nodal Dose Escalation + Ultrahypofractionated Whole-Pelvis Radiotherapy

2 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Treatments and conditions

Ablative Prostate Boost + Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Intermediate Nodal Dose Escalation + Ultrahypofractionated Whole-Pelvis Radiotherapy
Treatment and conditionWhere it standsTrials
Ablative Prostate Boost + Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Intermediate Nodal Dose Escalation + Ultrahypofractionated Whole-Pelvis Radiotherapy for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ablative Prostate Boost + Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Intermediate Nodal Dose Escalation + Ultrahypofractionated Whole-Pelvis Radiotherapy for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1